CRISPR Therapeutics AG
CRSPN MM
CRSPN MMCRISPR Therapeutics AG
Mexico Composite1,190.00
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Dr. Samarth Kulkarni Ph.D.
- Full Time Employees
- 458
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Baarerstrasse 14 Zug Switzerland 6300
- Website
- www.crisprtx.com
- Business
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Company News
CRISPR Therapeutics AG (CRSP) Outpaces Stock Market Gains: What You Should Know
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Why Is CRISPR Therapeutics (CRSP) Up 12% Since Last Earnings Report?
Buy Rating Justified for Crispr Therapeutics AG Amidst Optimistic Growth and Strategic Execution
BioLineRx stock jumps 14% on St. Jude clinical trial for mitoxafortide
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Crispr Therapeutics AG (CRSP) and Tango Therapeutics (TNGX)
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
Is CRISPR Therapeutics a Millionaire Maker?
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Vertex (VRTX) Outperforms Industry on Rapid Pipeline Progress
CRSP, NYMT and SBRA are among after hour movers
Why Cathie Wood’s ARK Innovation ETF is struggling in 2024 despite the stock-market rally
Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024
7 No-Brainer Stocks to Buy and Hold for the Next 20 Years: May 2024
Meme stocks are having a moment, but the broader market is rallying as well
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)